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 Autoantigens of Rat Experimental Autoimmune 
Uveitis 
 Experimental autoimmune uveitis (EAU) in Lewis 
rats is an intraocular inflammation leading to retinal de-
struction. The disease is mediated by CD4+ T helper 1 
(Th1) cells, which recruit inflammatory cells, mainly 
monocytes/macrophages. In the rat eye, both the anterior 
and the posterior parts are affected, whereas irreversible 
destruction is mainly observed in the retina. EAU can be 
induced by immunization with several retinal autoanti-
gens, of which retinal S-antigen (S-Ag) and interphotore-
ceptor retinoid-binding protein (IRBP) are best charac-
terized. The most pathogenic epitopes of these autoanti-
gens cover amino acids (AA) 341–354 of S-Ag (peptide 
PDSAg)  [1] and AA 1169–1191 of IRBP (R14)  [2] .
 Peripheral Induction of a Cross-Reactive Immune 
Response by Antigenic Mimicry 
 The immune privilege of the eye, maintained by the 
blood-retina barrier, anterior-chamber-associated im-
mune deviation (ACAID) and immunosuppressive me-
diators (i.e. TGF-  or   -melanocyte-stimulating hor-
mone (-MSH)), prevents ocular invasion of nonactivat-
ed leucocytes. Therefore, an autoimmune response 
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 Abstract 
 Experimental autoimmune uveitis (EAU) in Lewis rats is a 
well-established model for human uveitis. During the last 
years we used this model to demonstrate extraocular induc-
tion of uveitis by antigenic mimicry of environmental anti-
gens with retinal autoantigen and investigated the migra-
tion and intraocular reactivation of autoreactive green 
fluorescent protein (GFP)+ T cells. We could also elaborate 
several differences between EAU induced with S-antigen 
peptide PDSAg or R14, a peptide derived from interphotore-
ceptor retinoid-binding protein, suggesting two differently 
regulated diseases in the same rat strain. R14-mediated EAU 
in Lewis rats has been shown to relapse, thus we have a new 
model to test therapeutic approaches in an ongoing im-
mune response instead of just preventing disease. Finally, 
we show antigenic mimicry of PDSAg and an HLA-B peptide 
for oral tolerance induction. After the successful first thera-
peutic trial this approach will now proceed with internation-
al multicenter clinical trials.  Copyright © 2008 S. Karger AG, Basel 
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leading to intraocular inflammation has to be generated 
outside of the eye, and we postulate a cross-reactive non-
ocular antigen as the activator of T cells (antigenic mim-
icry). T cells activated to such a mimotope are then able 
to enter the eye because activated T cells can pass the 
blood-retina barrier. In the eye they are reactivated by 
cross-reactive retinal antigen. There is one exception to 
this mechanism of disease induction, which is sympa-
thetic ophthalmia. Here, the injury to one eye allows the 
entry of immune cells to ocular tissue and a direct gen-
eration of an ocular antigen-specific immune response.
 We could describe two mimotopes of retinal peptide 
 PDSAg, peptides derived from environmental antigens. 
One peptide, Cas, covers AA 73–84 of bovine milk   s2-
casein and is a typical nutritional antigen, the other, Rota, 
is derived from the outer capsid protein (AA 591–601) 
from gastroenteritis-causing rotavirus  [3] . Both peptides 
induce uveitis after immunization with complete Freund’s 
adjuvant (CFA), with a lower incidence but the same dis-
ease severity as with PDSAg. T cell lines specific for Rota 
and Cas are also pathogenic; moreover, they show cross-
reactivity to PDSAg in vitro. Not only Cas peptide but 
also   s2-casein protein is able to induce uveitis in Lewis 
rats. The disease is indistinguishable from PDSAg-in-
duced EAU with respect to clinical course and histology. 
Since nutritional antigens are normally applied to the 
gastrointestinal mucosa and not subcutaneously, we also 
tried to induce EAU by feeding the antigens together with 
native cholera toxin, which is a Th1-shifting gastrointes-
tinal adjuvant in rats. Only casein protein, but none of the 
peptides or S-Ag was able to induce EAU by the oral route, 
indicating that a gastrointestinal immune response to 
cross-reactive antigens might be a way to induce ocular 
autoimmune disease. Uveitis patients showed signifi-
cantly higher immune responses (T cells, antibodies) to 
retinal S-Ag, peptide and the mimotopes than healthy 
controls.
 Intraocular Reactivation of Cross-Reactive T Cells 
 To follow the migration of autoreactive T cells, we 
 injected antigen-activated, green-fluorescent-protein 
(GFP)-transduced R14- or ovalbumin (OVA)-specific 
control T cells intravenously into naive rats. The migra-
tion of fluorescent T cells was observed by daily intravital 
fluorescence microscopy of the iris  [4] . The first GFP+ T 
cells, irrespective of their specificity for autoantigen or 
OVA, extravasated and entered the iris tissue within 30 
min after injection. The number of GFP+ cells of either 
specificity gradually increased within the first 3 days. Af-
ter 3 days the number of OVA-specific GFP+ T cells de-
creased, whereas R14-specific T cells increased, accom-
panied by an infiltration of GFP– inflammatory cells. At 
this time point the clinical disease started, with ophthal-
moscopically visible infiltration of leucocytes. The time 
between the immigration of the first autoreactive T cells 
and the recruitment of inflammatory cells is probably the 
prodromal state, which patients with anterior uveitis 
sometimes experience as an ‘organ feeling’ or pain pre-
ceding a clinically visible relapse of uveitis.
 The invasion of ocular tissue by numerous OVA-spe-
cific T cells underlines the fact that activated T cells of 
any specificity can overcome the blood-retina barrier and 
enter the eye, but without causing destruction – unless 
they find their specific or cross-reactive antigen, and get 
reactivated. Staining for surface markers of T cell activa-
tion revealed that R14-specific GFP+ T cells are reacti-
vated in the eye, but neither in lymphoid organs nor in 
blood, whereas OVA-specific GFP+ T cells experience no 
reactivation. To prove that antigen-specific reactivation 
is sufficient to induce uveitis, we injected OVA into the 
anterior chamber after the adoptive transfer of OVA-spe-
cific T cell lines. In this case we induced ‘immunogenic 
uveitis’ and also observed upregulation of activation 
markers on OVA-specific T cells isolated from the eye. 
Therefore, reactivated T cells can recruit inflammatory 
cells that cause destruction of ocular tissues.
 Differences between EAU Induced with S-Ag 
Peptide PDSAg or IRBP Peptide R14 
 EAU in Lewis rats was regarded as an acute, monopha-
sic disease, until Shao et al.  [5] described relapsing disease 
after adoptive transfer of T cell lines specific for a peptide 
from IRBP (AA 1177–1191), which is an N-terminally 
truncated form of IRBP peptide R14.
 We observed relapses of EAU after immunization of 
rats with peptide R14 in CFA and could reinduce EAU 
after prior disease induction with R14-CFA or adoptive 
transfer or R14-specific T cell lines but not after primary 
PDSAg-mediated disease  [6] . T cell lines specific for R14 
or PDSAg are both of the Th1 type; however, in culture 
supernatants of R14-specific T cells we find higher con-
centrations of cytokines than in supernatants of PDSAg-
specific T cells, independent of the proliferation of the 
respective T cells  [7] .
 R14- and PDSAg-mediated EAU is furthermore dif-
ferently regulated with respect to chemokines. Disease 
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induced by adoptive transfer of PDSAg-specific T cells 
was completely blocked by injection of N-terminally 
 methionylated RANTES, a CCR1/CCR5 receptor antag-
onist, which had no effect on EAU induced by adoptive 
transfer of R14-specific T cells  [7] . We could furthermore 
observe differences in the preferential site of infiltration 
of cells in R14- and PDSAg-induced diseases: while in 
PDSAg-mediated EAU cells mainly invade the retina 
from the choroid by destroying the retinal pigment epi-
thelium, the cells in R14-mediated EAU immigrate main-
ly from the retinal vessels, destroying photoreceptors but 
not the retinal pigment epithelium.
 Taken together, these data suggest that we have two 
antigen-dependent model diseases for uveitis in the same 
strain of rats.
 Oral Tolerance Induction: Antigen-Specific 
Suppression as a Therapy of Uveitis 
 Highly specific tolerance induction to only hit the 
 autoaggressive immune response without impeding the 
general immune defense is a desired therapeutic approach 
for autoimmune diseases ( fig. 1 ). Oral tolerance is a way 
to induce antigen-specific tolerance by feeding the re-
spective (auto)antigen.
 In the rat model, feeding of S-Ag or the peptide PDSAg 
can suppress S-Ag-induced EAU, and feeding IRBP sup-
presses IRBP-induced uveitis. We described a peptide de-
rived from the sequence of HLA-B antigens that is called 
B27PD, although it is not only B27-specific. This peptide 
shares AA sequence homologies with peptide PDSAg and 
can serve as oral tolerogen to suppress EAU induced with 
 Fig. 1. Autoaggressive T cells in uveitis: peripheral induction, in-
traocular reactivation and therapeutic suppression by oral toler-
ance. (1) Naive T cells are activated outside of the eye (peripheral 
lymph nodes) by presentation of environmental antigens, which 
are cross-reactive with retinal autoantigen (e.g. bovine milk ca-
sein, rotavirus outer capsid protein). They become Th1 cells that 
secrete IL-2, IFN-  and TNF-  . Once activated, these T cells are 
able to pass the blood-retina barrier and find a cross-reactive au-
toantigen within the eye. APC = Antigen-presenting cell. (2) In-
traocular antigen contact leads to reactivation of the Th1 cells.
(3) Subsequently, Th1 cells secrete chemokines and cytokines to 
attract inflammatory cells (rat EAU: mainly monocytes/macro-
phages). (4) EAU can be suppressed by oral application of the ret-
inal autoantigen/peptides used for experimental induction of dis-
ease. An HLA-class I B-derived peptide mimotope of S-Ag peptide 
PDSAg, B27PD, serves as oral tolerogen as well, whereas the mim-
icry peptides from rotavirus and bovine casein have no tolero-
genic effect. The regulatory cells (Ts) are activated in the gut-as-
sociated lymphoid tissue (GALT) by the presentation of a respec-
tive tolerogen. They migrate in search of their antigen and of 
respective specific T effector cells outside the GALT, where they 
downregulate the activity of the Th1 effector cells in peripheral 
lymph nodes or probably also in the final target organ, the eye. 
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S-Ag protein, peptide PDSAg and even IRBP protein  [1] . 
Although the homology of IRBP and HLA peptide B27PD 
is not yet elucidated, data from equine uveitis also point 
to a cross-reactivity  [8] . We could transfer protection 
from uveitis to naive rats by    T cells isolated from the 
spleens of orally tolerized rats  [9] . These    T cells pro-
liferate in vitro in response to their respective antigen 
peptide or mimotope (PDSAg or B27PD), and    T cells 
serve as antigen-presenting cells. The proliferation of 
these    T cells is dependent on CD8   and MHC class 
II, as shown by the strong inhibitory effect of antibodies 
to CD8  and RT1.B, which is the restriction element of 
the tolerogenic peptides PDSAg and B27PD  [10] .
 While we could induce severe EAU with peptides 
 PDSAg, Cas and Rota, but not with B27PD, we were only 
able to induce tolerance to PDSAg-induced uveitis by 
feeding PDSAg or B27PD, but not using Rota or Cas, in-
dicating that pathogenic antigens are not mandatorily 
tolerogenic and vice versa  [10] .
 The high tolerogenicity accompanied with low patho-
genicity makes peptide B27PD a highly interesting can-
didate for oral tolerance induction in patients.
 We had therefore performed a therapeutic trial for pa-
tients with autoimmune uveitis  [11] , who were taking 
4 mg of encapsulated peptide B27PD 3 times a week for 
12 weeks. All 8 patients could lower their corticosteroid 
doses either during or after oral peptide application with 
stable or increased visual acuity. During a 5-year follow-
up 2 patients needed immunosuppressive therapy again 
(1 patient after 3 years, 2 after 4 and 5 years), but the av-
erage daily corticosteroid dose remained stable and sig-
nificantly lower compared to the dose prior to oral pep-
tide therapy.
 An international multicenter trial with oral peptide 
B27PD for uveitis patients is in preparation.
 Taken together, with the rat model leading to a new 
therapy for uveitis patients and the recent observations of 
relapsing as well as reinducible disease and the differenc-
es in regulation by chemokine receptors, we have a high-
ly valuable model for human uveitis. 
